I am so tired of believing in this Company and watching my investment drift down into serious loss territory. I have to admit that in over a dozen years of own GERN stock, I still feel like I care more about the Company than the CEO and his lap dogs---no matter who the present CEO is. I'm beginning to believe they have to agree to a non performance clause when they interview for management positions at GERN.
I've seen a lot of guys that are professional bod bodies. They get paid well for their time, it looks good on their resumes and at the Country Club, but they just bring a warm seat to the Board, and nothing else. Looks like Huh fits that bill of being a professional BOD member.
I have an AMTD US account and I was able to purchase GGG.V via a broker assisted trade using a placeholder symbol. a few weeks ago That placeholder has been converted to GPHBF. It isn't trading as of Sept. 5th under that OTC symbol, but I expect it to do so very very shortly.
All those pricks have to do is throw a .10 tax per transaction, and that would end it. But that would get in the way of the revolving door hiring of lackeys once they retire from their lazy azzed jobs at the SEC
Novartis reception vs. Geron's a brief quote:
A new study reports one of the biggest potential advances against heart failure in more than a decade — a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 percent.
Doctors say the Novartis drug — which doesn't have a name yet — seems like one of those rare, breakthrough therapies that could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.
"This is a new day" for patients, said Dr. Clyde Yancy, cardiology chief at Northwestern University in Chicago and a former American Heart Association president.
"It's been at least a decade since we've had a breakthrough of this magnitude," said Yancy, who had no role in the study.
It involved nearly 8,500 people in 47 countries and was the largest experiment ever done in heart failure. It was paid for, designed and partly run by Novartis, based in Basel, Switzerland. Independent monitors stopped the study in April, seven months earlier than planned, when it was clear the drug was better than an older one that is standard now.
During the 27-month study, the Novartis drug cut the chances of dying of heart-related causes by 20 percent and for any reason by 16 percent, compared to the older drug. It also reduced the risk of being hospitalized for heart failure by 21 percent.
"We are really excited," said one study leader, Dr. Milton Packer of UT Southwestern Medical Center in Dallas. The benefit "exceeded our original expectations."
The pros may be beating GERN into the deck, but if you look at INCY Jan 2016 Puts, they are very expensive, indicating that the players don't have a lot of hope of INCY NOT crashing.
FABULOUS results!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Thanks
Plus the new level of short manipulative posts on this board is fascinating. Almost all the posters here have been placed on ignore, as their goal is to obfuscate any relevant posts and discourage investors.
Yes, I noticed, most of them buys, but the algos and working hard at slamming the price down. The march of the algos is tough. The vol. with no news is unusual.
"...... but these days biotech shorts are the most dangerous of all because there is so much imagination involved and so few data points. "
Geron will react to the CC in after hours trading. If it is the news we all expect, there will be panic buying by shorts to cover, and there will be limited sellers. This should spike the price. Since GERN has elected to present this blockbuster news during the after hours period, I believe they are fully aware of what will happen to the SP, and probably have a couple of magnums of champagne on ice as they watch the short panic.
STOPPING HEMATOLOGICAL CANCER:
New Drug Induces Remissions in Myelofibrosis
The results of a Mayo Clinic study demonstrate that
a drug named imetelstat induces remissions in some
patients with myelofibrosis. This is a form of chronic
leukemia that affects the patient’s bone marrow
that is replaced by fibrosis (scar tissue) instead
of blood-producing cells.
Scientists do not yet know the exact mechanism of
acttion for imetelstat, but believe it interferes with the
survival and proliferation of cancer cells by inhibiting
a critical enzyme called telomerase. One of the functions
of telomerase is to repair the ends of chromosomes
called telomeres, and because cancer cells have shorter
than normal telomere size, they are particularly susceptible
to the drug.
The study results are promising. Some patients
participating in the clinical trial taking imetelstat obtained
dramatic responses, and we have seen some complete
responses (tantamount to a cure), which is almost
unheard of in this disease.
THE NEED TO DISCOVER, IMPROVE, AND ADVANCE
Research is the fundamental reason that people across
the globe are living longer, healthier lives.
Mayo Clinic applies basic science to unlock the
destructive secrets of cells and discover how to repair
or reverse the damage. We then translate that knowledge
into first-time cures and treatments for a wide range
of life-threatening diseases and chronic conditions.
Patients receive research-driven care at Mayo Clinic,
which possesses a long legacy of providing a
team-based approach to integrating patient care,
research, and education.
9 UNLOCKING THE SECRETS OF CELLS • MAYO CLINIC BIOMEDICAL RESEARCH
Although patients may experience relief in response
to other treatments, their bone marrow does not
usually return to normal. But in the case of this new
therapy, some of the patients participating in the trial
developed normal bone marrow.
Researchers studied imetelstat in 33 patients at
Mayo Clinic and have now followed the first 22 patient
Just took a quick run through on the discussions you brought to our attention. Smart people saying complicated things. Easy enough for the uneducated to skim and get a sense of the promise held out, though.
Just wanted to add (for others' benefit ) after reading this post of yours, I went back and read all the posts you've contributed over the last 3 months. I have to say you have a ring of credibility though out all your posts,
when viewed through a retrospective lens that lends credence to this post. So, I'm a fan and looking forward to the 11th.
One can surmise until the cows come home, but a quick scan of the last hours trading clearly indicate a determined effort to keep the share price down. Whether it is generic shorts or competing drug cos. the nefarious plan is obvious when you look at the minute chart.
Nice to see some buying with conviction.
Gern is one heck of a buy. Probably see a 50% bump on the 11th CC. Then it is just a question whether to hold or take the quick profit. Holding for two years will probably make you a lot of money. One aspect to investing at this point in time in a bio tech like GERN is that it is largely independent of the overall market--once it starts to move. And, if you believe we are on the edge of the mother of all pullbacks, then it is another reason to buy.